CA2247946A1 - Anticachectic composition - Google Patents

Anticachectic composition

Info

Publication number
CA2247946A1
CA2247946A1 CA002247946A CA2247946A CA2247946A1 CA 2247946 A1 CA2247946 A1 CA 2247946A1 CA 002247946 A CA002247946 A CA 002247946A CA 2247946 A CA2247946 A CA 2247946A CA 2247946 A1 CA2247946 A1 CA 2247946A1
Authority
CA
Canada
Prior art keywords
bond
substituted
ring
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002247946A
Other languages
French (fr)
Other versions
CA2247946C (en
Inventor
Yu Momose
Etsuya Matsutani
Takashi Sohda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries, Ltd.
Yu Momose
Etsuya Matsutani
Takashi Sohda
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP9027957A external-priority patent/JPH09323930A/en
Application filed by Takeda Chemical Industries, Ltd., Yu Momose, Etsuya Matsutani, Takashi Sohda, Takeda Pharmaceutical Company Limited filed Critical Takeda Chemical Industries, Ltd.
Publication of CA2247946A1 publication Critical patent/CA2247946A1/en
Application granted granted Critical
Publication of CA2247946C publication Critical patent/CA2247946C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Abstract

A medicinal composition for the prophylaxis and treatment of cachexia which comprises a compound of formula (I) wherein R
represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula -CO-, -CH(OH)-, or -NR3- (R3 represents an alkyl group that may be substituted); m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A
represents a bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulphur; R1 represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R1; L and M
respectively represent hydrogen or may be combined with each other to form a bond, provided that when m and n are O, X represents CH, A represents a bond, Q represents sulfur, R1, L and M respectively represent hydrogen, and ring E does not have further substituents, R
does not represent dihydrobenzopyranyl; or a salt thereof.
CA002247946A 1996-04-04 1997-04-03 Anticachectic composition Expired - Fee Related CA2247946C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP8284596 1996-04-04
JP8/82845 1996-04-04
JP9027957A JPH09323930A (en) 1996-04-04 1997-02-12 Preventive and treating agent for cachexia
JP9/27957 1997-02-12
PCT/JP1997/001148 WO1997037656A1 (en) 1996-04-04 1997-04-03 Anticachectic composition

Publications (2)

Publication Number Publication Date
CA2247946A1 true CA2247946A1 (en) 1997-10-16
CA2247946C CA2247946C (en) 2006-10-03

Family

ID=37101797

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002247946A Expired - Fee Related CA2247946C (en) 1996-04-04 1997-04-03 Anticachectic composition

Country Status (1)

Country Link
CA (1) CA2247946C (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278914B2 (en) 2004-06-07 2016-03-08 University Of Tennessee Research Foundation SARMs and method of use thereof
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US11090283B2 (en) 2007-09-11 2021-08-17 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278914B2 (en) 2004-06-07 2016-03-08 University Of Tennessee Research Foundation SARMs and method of use thereof
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US10053418B2 (en) 2004-06-07 2018-08-21 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US10662148B2 (en) 2004-06-07 2020-05-26 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US10300037B2 (en) 2006-08-24 2019-05-28 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US11090283B2 (en) 2007-09-11 2021-08-17 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)

Also Published As

Publication number Publication date
CA2247946C (en) 2006-10-03

Similar Documents

Publication Publication Date Title
TW268952B (en)
AU3461697A (en) Heterocyclic compounds, their production and use
CA2247443A1 (en) Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma
IL144170A0 (en) 4-oxo-1,4-dihydro-3-quinolinecarboamides as antiviral agents
HK1072770A1 (en) Bicyclic compound
MY100124A (en) Dihydropyridazinones.
FR2672598B1 (en)
AU1172999A (en) Novel apoptosis inhibitors
WO1999009965A3 (en) Anti-inflammatory agent
AU2177997A (en) Anticachectic composition
IE841659L (en) Allopurinol prodrugs
CA2247946A1 (en) Anticachectic composition
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
CA2014490A1 (en) Diaminoethylene compounds
WO2001010834A3 (en) Antibacterial agents
EP0288969A3 (en) Antiulcer composition
ES8605810A1 (en) Penem derivatives and precursors.
IE44316L (en) Indazole derivatives.
TW328957B (en) Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
PL222294A1 (en)
WO1999023092A3 (en) 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them
GR3004851T3 (en)
IE44180L (en) Azaprostaglandins.
ES8607963A1 (en) Tricyclic imidazole derivatives.
ZA825576B (en) Benzodioxane-imidazoline compounds as antihypertensives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed